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Background: Cervix cancer, preventable, continues to be the third most common cancer in women worldwide,
especially in lowest income countries. Prophylactic HPV vaccination should help to reduce the morbidity and
mortality associated with cervical cancer. The purpose of the study was to describe the results of and key concerns
in eight HPV vaccination programs conducted in seven lowest income countries through the Gardasil Access
Program (GAP).
Methods: The GAP provides free HPV vaccine to organizations and institutions in lowest income countries. The
HPV vaccination programs were entirely developed, implemented and managed by local institutions. Institutions
submitted application forms with institution characteristics, target population, communication delivery strategies.
After completion of the vaccination campaign (3 doses), institutions provided a final project report with data on
doses administered and vaccination models. Two indicators were calculated, the program vaccination coverage and
adherence. Qualitative data were also collected in the following areas: government and community involvement;
communication, and sensitization; training and logistics resources, and challenges.
Results: A total of eight programs were implemented in seven countries. The eight programs initially targeted a
total of 87,580 girls, of which 76,983 received the full 3-dose vaccine course, with mean program vaccination
coverage of 87.8%; the mean adherence between the first and third doses of vaccine was 90.9%. Three programs
used school-based delivery models, 2 used health facility-based models, and 3 used mixed models that included
schools and health facilities. Models that included school-based vaccination were most effective at reaching girls
aged 9-13 years. Mixed models comprising school and health facility-based vaccination had better overall
performance compared with models using just one of the methods. Increased rates of program coverage and
adherence were positively correlated with the number of vaccination sites. Qualitative key insights from the school
models showed a high level of coordination and logistics to facilitate vaccination administration, a lower risk of
girls being lost to follow-up and vaccinations conducted within the academic year limit the number of girls lost
to follow-up.
Conclusion: Mixed models that incorporate both schools and health facilities appear to be the most effective at
delivering HPV vaccine. This study provides lessons for development of public health programs and policies as
countries go forward in national decision-making for HPV vaccination.
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As of 2008, cervical cancer is the third most common
cancer in women, and the seventh most common cancer
overall. It is estimated that 530,000 new cases of cervical
cancer were diagnosed in 2008, of which 85% occurred
in less developed countries. In these countries, cervical
cancer accounts for 13% of all female cancers. There
were 275,000 deaths from cervical cancer in 2008 and,
consistent with the incidence data, 88% of deaths oc-
curred in developing countries [1]. Due to the relatively
young age of women who develop cervical cancer, the
disease is the single biggest cause of age-weighted years
of life lost in the developing world [2].
Human papillomavirus (HPV) is found in 99.7% of cer-
vical cancers worldwide, and HPV infection is considered
a necessary cause of the disease [3]. Although multiple
HPV types are associated with increased risk of develop-
ing high-grade cervical lesions that are precursors to cer-
vical cancer, HPV-16 and HPV-18 are associated with
almost 70% of such lesions [4]. Consequently, prophylac-
tic vaccination against HPV, particularly types 16 and 18,
reduce the incidence of cervical cancer by reducing the
incidence of HPV infection. Two prophylactic HPV vac-
cines have been available since 2006 and have high effi-
cacy (>90%) for preventing high-grade cervical lesions
associated with HPV-16 and HPV-18 [5-9]. An analysis
of cervical screening and immunization practices in
Latin America and the Caribbean suggests that imple-
mentation of a universal HPV vaccination program in
the context of a revised cervical cancer screening policy
is the best prospect for reducing the incidence of cervical
cancer in the region [10].
Despite the efficacy and availability of prophylactic
HPV vaccines, a number of barriers have limited their
uptake in low-resource settings, including: cost; difficulty
in effectively reaching HPV vaccine target populations;
competition for immunization resources as vaccines
against other diseases are also being introduced; cultural
issues related to the fact that HPV infection is a sexually
transmitted disease; limited awareness of cervical cancer
and its relationship to HPV infection; concerns about
HPV vaccination with respect to safety and future fertil-
ity; negative experiences with previous vaccinations for
other diseases; and political factors [11-18]. Another key
challenge for implementing national HPV vaccine pro-
grams in the developing world is determining which fa-
cilities and personnel will deliver the vaccine [19,20].
In an effort to address these challenges and identify ef-
fective processes for implementing HPV vaccination
among adolescent girls in low-resource settings, Axios
Healthcare Development is managing the Gardasil Ac-
cess Program (GAP) and is the recipient of the Gardasil
donation following a pledge by Merck & Co., Inc to do-
nate at least 3 million doses of GardasilW [HumanPapillomavirus Quadrivalent (Types 6, 11, 16 and 18)
Vaccine, Recombinant]. Projects supported by the GAP
are developed and implemented by local, in-country
organizations or institutions. While participating pro-
grams receive a donation of HPV vaccine doses through
GAP, they are otherwise supported entirely by their re-
spective countries. A key component of the GAP is to
capture the experiences and lessons learned by partici-
pating programs and institutions, and to leverage this
knowledge to improve HPV vaccine access and child/
adolescent immunization models. The success of each
program and its ability to address the challenges listed
above were assessed in order to identify trends, similar-
ities, and differences among various strategies, and to le-
verage this knowledge to inform future HPV vaccination
efforts.
The aim of this study was to describe the results of
and key concerns in eight HPV vaccination programs
conducted in seven lowest income countries through the
Gardasil Access Program (GAP).
Methods
Setting
The GAP provides free vaccine to organizations and
institutions in eligible lowest income countries, includ-
ing the 3 doses of the vaccine required for a complete
vaccination series. While participating projects receive
free vaccine, they are then responsible for covering costs
related to the importation, transportation, storage and
distribution of vaccine, as well as costs for community
outreach, efforts to promote the program, management
of the project and data collection. The GAP enables
organizations and institutions in eligible lowest income
countries to gain operational experience designing and
implementing HPV vaccination programs. The GAP also
encourages applicants to follow World Health
Organization (WHO) recommendations and guidelines
for HPV vaccination, with respect to both target popula-
tions and safety vaccine administration protocols par-
ticularly in the vaccination of girls within the 9-13 years
age range [21]. It should be noted that three programs
were approved prior to the issuance of the WHO guide-
lines recommending HPV vaccination for girls aged 9-
13 years.
Inclusion procedures
Each institution interested in participating in the GAP
submitted a completed application form, which collected
standardized information about the primary institution,
including institution type, core competencies, and catch-
ment area; collaborating organizations; vaccine program
activities (vaccination experience, vaccination proce-
dures); training in vaccine administration and injection
safety procedures; services available to store, administer,
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(obtaining parental/caregiver consent, type of delivery
model, vaccination schedule); operational activities
(communications and sensitization of key stakeholders),
requested vaccine (number of vaccination sites, number
of expected participants and target population).
Independent experts evaluated the submitted applica-
tion using a standardized review form and made recom-
mendations on acceptance or rejection of demand. The
GAP Advisory Board then undertook a final review of
each application and provided recommendations for
final approval.
Project follow-up
Participating institutions are required to submit a final
project report after completion of the vaccination cam-
paign (3 doses). Data included in this final report were:
disposition of vaccine doses; number of girls receiving
each dose of Gardasil, stratified inside or outside the 9-
13 year age range; target audiences, key messages, meth-
ods of communication, and reactions and lessons
learned with respect to communicating with stakeholder
groups; cold chain logistics and distribution results; and
program costs. Data on vaccine delivery models and
point of vaccination were also submitted.
The programs used three models for vaccine delivery:
school-based models administered vaccine at local
school facilities; health facility-based models adminis-
tered vaccine at health facilities, hospitals and mobile
clinics; and mixed models used both schools and clinics
to deliver vaccine.
Vaccination indicators
The effectiveness of each program was determined based
on two indicators: program vaccination coverage and
vaccination adherence. Estimated program vaccination
coverage was defined as the number of girls receiving all
3 doses of vaccine divided by the number of girls origin-
ally targeted by the project. Each program used different
factors to determine the target population. Programs
using health facility-based or mixed models utilized
population data for the geographic area included in the
campaign. Information on the number of inhabitants
and number of girls included in the vaccination age
range living in a specific geographic area was obtained
used to calculate the target population for the vaccin-
ation program. With this methodology, the target popu-
lation calculation is directly impacted by errors or
inaccuracies in the census data. Programs using school-
based models based their target population calculation
on the number and age of girls registered at participat-
ing schools. Vaccination adherence was defined as the
number of girls receiving all 3 doses of Gardasil divided
by the number of girls who received a dose of vaccine.Adherence measures were calculated between dose (D)2
and D1, between D3 and D2 and between D3 and D1.
All programs adhered to the standard Gardasil vaccine
schedule.
For the qualitative analysis, textual data were extracted
from application forms and progress reports and then
indexed. This enabled the generation of specific analyt-
ical categories: government and community involve-
ment; media, communication, and sensitization; training
and human resources; challenges; and 3 models defined.
Original texts were used to illustrate the results of the
qualitative analysis [22].Qualitative analysis
Qualitative data on a variety of indicators were systemat-
ically collected and analyzed for each program in the
form of field notes and transcripts. These indicators
were: government and community involvement (discus-
sions with parents and their girls; financial contribution)
media, communication, and sensitization (HPV vaccin-
ation program and cervical cancer prevention); training
and logistic resources; and challenges in executing the
program as designed. The analysis was conducted
according to the three defined delivery models. The
qualitative data were preserved in textual form and then
indexed to generate analytical categories. Two separate
analyses were performed independently, and the results
were merged and evaluated in order to generate themes
that captured the range of experiences and views
reported.
Three criteria were used to assess community involve-
ment: participation of the community in the diffusion of
information about the vaccination campaign; active role
of community in the announcement of the three vaccin-
ation sessions; and participation of the community in
the follow up of girls (reducing the number of partici-
pants lost to follow-up). Community involvement was
qualified as “strong” if the three criteria were present,
“medium” if two criteria were met, and “low” if only one
criterion was satisfied.Statistical analysis
The Mann–Whitney test was used when appropriate.
Comparisons between vaccination program coverage
and adherence to vaccination between first and third
dose and the three vaccination delivery models were
tested by Kruskal-Wallis test. Correlation between the
number of vaccination sites and the program vaccination
coverage was tested using the Spearman correlation rank
(rs). For all analyses, a significance level of 0.05 was used.
Statistical analyses were carried out in StatviewW 5.0
SAS (SAS Institute Inc.).
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A total of eight programs implemented in seven countries
were included: Bhutan, Bolivia, Cambodia, Cameroon,
Haiti, Lesotho, and Nepal. The baseline characteristics of
these programs are presented in Table 1. Projects in Bhu-
tan, Bolivia (1), Cambodia, Haiti and Lesotho were
initiated in 2009; projects in Bolivia (2), Cameroon, and
Nepal were initiated in 2010.
Table 2 summarizes by program the vaccination deliv-
ery model, number of vaccination sites, the number of
girls targeted for vaccination, the number of girls receiv-
ing the full vaccine course, the percentage of girls com-
pleting the vaccine course who were 9-13 years of age,
estimated program coverage and adherence rates. The
eight programs initially targeted a total of 87,580 girls
(range [R] = 1,600–40,100), of which 76,983 (R = 1,033–
33,818) received the full 3-dose vaccine course. This cor-
responds to an overall estimated program coverage rate
of 87.8% (R = 64.5%-107.4%). Projects with coverage
> 100% delivered 3 doses of vaccine to a greater number
of girls than originally targeted. Between D3 and D1, the
mean program adherence was 90.9% (R = 75.8%-98.7%).
The number of vaccination sites was positively corre-
lated to the program vaccination coverage (rs = 0.46,
p = 0.29).
Program vaccination coverage and adherence were
also stratified for the three vaccination delivery models
(Table 3). The health facility model had a lower rate of
coverage (77.1%) than programs using a mixed model
(93.8%) or a school model (93.0%) (p = 0.74). With re-
spect to program adherence between D3 and D1, the
mixed model was most effective (96.6%), intermediate
for the school model (88.6%) and the health facility
model was least effective (79.7%) (p = 0.39). The esti-
mated coverage was 94.9% for the 5 programs that vacci-
nated girls in the range of 9-13 years, and 80% for the
three programs that vaccinated outside that age range
(p = 0.25). Program adherence was 91.0% for the projectsTable 1 Characteristics of the 8 HPV vaccinations project incl




1 Bhutan MoH Mixed
2 Bolivia NGO Mixed
3 Bolivia NGO Mixed
4 Cambodia MoH Urban
5 Cameroon NGO Mixed
6 Haiti NGO Rural
7 Lesotho MoH Mixed
8 Nepal NGO Mixed
NGO: Non-Governmental Organization.
MoH: Ministry of Health.
* Bhutan: age repartition: data not available.within the 9-13 years age range, and 84.3% for programs
vaccinating outside the range (p = 0.49).
A variety of communication vehicles were used, in-
cluding community meetings informational posters,
flyers, television, radio, and newspapers. Many programs
mentioned the need to include basic information on cer-
vical cancer in very plain language, and this was particu-
larly challenging in Bolivia and Lesotho, in which local
language equivalents for “cervix” do not exist.
Community involvement was strong in five of the
seven programs for which data were available (data were
not available for the project conducted in Bhutan),
medium in one project and low in one project. Strong
community involvement was reported for the definition
of key messages, recruitment of participants and follow-
up with participants. The community was involved in
the announcement of the vaccination sessions in less
than 30% of the projects.
Qualitative results from the Haiti project suggest that
establishing formal involvement of community members
in all aspects of the project ensured community owner-
ship. In Cambodia and Cameroon, a voluntary small fi-
nancial contribution to cover the administrative costs of
participation ensured that communities and families per-
ceived an intrinsic value in the vaccine and vaccination
services while also helping support a minimal part the
costs of the program. Experiences in the Cameroon pro-
ject also suggest that more in-depth discussion sessions
with parents and caregivers, and evaluation of the know-
ledge of and attitudes toward HPV vaccination in these
audiences will be important to the success of future
HPV vaccination campaigns. Establishing a status
symbol type reward for girls who complete the full vac-
cine course, such as bracelet (Nepal) or T-shirt (Haiti)
helped to create demand for the vaccine among the girls
themselves.
Qualitative analysis of the eight programs identified
several trends and common issues. Key insights from theuded in the Gardasil Access Program, 2009-2011
Vaccination
delivery model
Girls age group Number of
vaccination
sites
School 9-13 years* 9
School 9-13 years 57
Mixed 9-13 years 258
Health facility 11-18 years 1
Health facility 9-18 years 20
School 9-13 years 7
Mixed 10-18 years 47
Mixed 9-13 years 24























Adherence to vaccination %
Between Between Between
D2-D1 D3-D2 D3-D1
1 Bhutan School 9 3,200 2,721 2,721 (100)* 85.0 96.8 91.3 88.3
2 Bolivia School 57 3,480 3,739 3,739 (100) 107.4 99.8 96.6 96.1
3 Bolivia Mixed 258 30,900 27,597 27,597 (100) 89.3 99.5 98.0 96.2
4 Cambodia Health facility 1 2,000 2,027 186 (9.2) 101.3 98.2 97.0 95.3
5 Cameroon Health facility 20 1,600 1,033 629 (60.9) 64.5 93.5 89.1 83.3
6 Haïti School 7 3,300 2,884 2,884 (100) 87.4 86.7 87.3 75.8
7 Lesotho Mixed 47 40,100 33,818 24,148 (71.4) 84.3 94.9 98.5 93.4
8 Nepal Mixed 24 3,000 3,164 3,164 (100) 105.5 99.7 98.9 98.7
Total - 423 87,580 76, 983 65,068 (80.4) 87.8 96.1 94.5 90.9
* Bhutan: age repartition: data not available.
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logistics are needed to facilitate vaccination administra-
tion; (ii) there is a lower risk of girls being lost to follow-
up; (iii) loss to follow-up was often associated with
transfer of students to new schools, family migration,
holidays and school calendar conflicts; (iv) vaccinations
should be conducted within the academic year to limit
the number of girls lost to follow-up.
Key benefits identified with clinic models were: (i) im-
mediate adverse events reports are exhaustively collected
in the clinic setting; (ii) the routine presence of human
and other resources needed to administer vaccine facili-
tated administration of vaccine outside of the planned
vaccination schedule; (iii) clinic sites had vaccine storage
facilities readily available onsite.
The mixed models exhibited key points from both the
school and clinic models. In the mixed models, the avail-
ability of clinic resources helped to ensure vaccination of
those girls who missed their vaccination day at school.
The increase in the number of vaccine distribution sitesTable 3 Number of HPV-vaccinated girls and vaccination adh














School 3 9,344 93.0
Health facility 2 2,742 77.1
Mixed 3 64,897 93.8required the continual evaluation of cold chain capacity
at schools and on going monitoring of the distribution
and stock of vaccine across various sites.
Discussion
Overall, the eight programs included in this study per-
formed very well by the two indicators used. Mean pro-
gram coverage across all programs was 88% and mean
adherence between D3 and D1 was 91%. The highest
program vaccination coverage was reported in the Bo-
livia 1 program. Such a high coverage rate in a school-
based model was somewhat unexpected. However, it
should be noted that there was a high demand for HPV
vaccination from other nearby schools not originally
included in the program. The program manager and
health authorities extended the vaccination period for an
additional two weeks in order to accommodate this de-
mand. Due to the extended time frame and the inclusion
of girls from schools not included in the initial targeting
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greater than 100%.
School-based vaccination delivery methods were most
effective at reaching girls within the WHO-
recommended age range, which is likely due to the fact
that girls aged 9-13 years are not usual “clients” of the
health care system. Additionally, few health systems have
robust follow-up systems in place for ensuring that par-
ticipants visit the clinic for each of the three scheduled
vaccinations. It should also be noted that the Cambodia
project, which used a health facility-based model, was
approved prior to the issuance of the WHO age recom-
mendations for HPV vaccination and included girls older
than 13 years of age. This certainly contributed to the
lower percentage of girls within the age range for health
facility-based models compared with the other models.
However, school-based projects faced several chal-
lenges when vaccination dates occurred outside of
scheduled school days. It was exponentially more diffi-
cult to prevent loss to follow-up in these instances and
in some cases, clinic and/or door-to-door follow up was
necessary to complete the 3 doses.
Interestingly, there was a trend toward increased rates
of project coverage and project adherence with an in-
creasing number of vaccine administration sites. This
trend makes sense given that more sites increase the
capacity for vaccine administration and, in fact, vaccine
utilization is higher when administration sites are easily
accessible [20]. However, it was not necessarily a given
that small pilot programs such as those described here
would have the resources or expertise to successfully
manage multiple sites. These results suggest that local
organizations can successfully implement relatively lar-
ger HPV vaccination campaigns and that additional sites
should be considered in order to increase access to and
delivery of HPV vaccines.
Mixed models yielded better overall performance (pro-
gram vaccination coverage and adherence indicators)
compared with school or clinic models. This may be due
to promotion of the program through health and educa-
tional channels. Community participation appeared to
be a less effective recruitment driver than channels that
utilized schools and clinics. The ability to deliver vaccin-
ation at school or a clinic site increased the likelihood
that participants would receive their vaccinations on
time even in cases of school relocation, family migration
or vaccination schedules that coincided with school holi-
days. Adherence in school-based models may also have
been negatively affected by the 2010 earthquake in Haiti,
which occurred between D2 and D3 of the school-based
Haiti program.
The feasibility and success of a similar mixed model
has also recently been demonstrated in Peru [23]. The
data show that inclusion of HPV vaccination did notdiminish health facilities’ capacity to administer routine
infant vaccination programs. Additionally, an analysis of
HPV vaccine acceptability in Botswana found that public
or community clinics would be the most common place
at which people would get HPV vaccine and that 74% of
study participants indicated that they would have their
daughters vaccinated against HPV at school if the vac-
cine was available there[16]. These findings further sup-
port the utility of a mixed model encompassing both
school and clinic-based vaccine delivery.
Based on the success and challenges of these eight
GAP programs, it is recommended that future programs
should conform to local norms for other vaccinations
with respect to signed consent by girls and their families
who chose to receive HPV vaccination. Additionally,
specific resources should be allocated to sensitize and
train schoolteachers to assist in recruitment of and
follow-up with girls during HPV vaccination campaigns.
Such training was deemed an essential component to
the success of a school-based HPV vaccine program in
Peru [23]. Teachers and headmasters were also consid-
ered decision-makers with respect to school-based HPV
vaccination in Peru, Uganda and Vietnam, and schools
were identified as effective sources for community health
education programs about cervical cancer [11,12]. Effect-
ive use of schools as venues for HPV vaccine programs
has also been identified as an important factor in the
successful adoption of HPV vaccine in low-resource set-
tings [19].
The high levels of estimated coverage and vaccination
adherence achieved with these programs could be due to
their relatively small size and close monitoring, and the
fact that resources have been allocated to them specific-
ally to conduct HPV vaccination activities. For the
current design of the GAP, the analyses of these projects
are a measure of the ability of a project or institution to
recruit participants and ensure that they receive all 3-
vaccine doses. These analyses do not assess the ability of
a project or institution to provide HPV vaccine coverage
to an entire population. Consequently, the two indica-
tors used to assess programs undertaken are distinct
from those related to measuring vaccine coverage.
In addition to a small sample size of only eight pro-
grams, this study has several limitations. The use of cen-
sus data to determine the number of eligible girls within
the geographic regions of health facility-based or mixed
model programs is an imprecise methodology that could
give rise to errors in determining target population.
Given that target population is the denominator in the
calculation used to determine program vaccine coverage,
error in determining the number of eligible girls who
could participate in a program will impact coverage
rates. This potential for error is somewhat less of an
issue in the three programs that used school-based
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than census data. Although population density could
also impact program vaccination coverage, data on
population density were not systematically collected and
were thus not included in the analysis reported here.
Three programs had program coverage greater than
100%: Bolivia 1 (school-based model), Cambodia
(health-facility model), and Nepal (mixed model). It is
possible that errors in the census data used to calculate
the denominator of the coverage estimation account for
these results in the Cambodia and Nepal programs.
However, it is also possible that demand for HPV vaccin-
ation near to but not within the original coverage area
resulted in the recruitment of more girls than expected.
Information campaigns and community involvement
may have been more effective than expected in some
areas or programs, which also could have increased re-
cruitment above original estimates. However, it is also
possible that demand for HPV vaccination near to but
not within the original coverage area resulted in the re-
cruitment of more girls than expected. Information cam-
paigns and community involvement may have been
more effective than expected in some areas or programs,
which also could have increased recruitment above ori-
ginal estimates.
Cost analysis data and model projections on cost-
effectiveness of different HPV vaccination programs in
low- and middle-income countries are not included be-
cause the cost data collected were incomplete. Addition-
ally, the projects reported on here are pilots developed
at the community level, and may not be applicable to
larger regional or national campaigns that may comprise
diverse socio-economic, religious, and cultural constitu-
encies. Optional preventive strategies, regional strategies,
or mixed strategies in rural low-income regions could
play an important role in addressing the challenges asso-
ciated with HPV vaccine coverage, access, and accept-
ance [24]. Data from the projects described here may
enable diverse approaches that allow individual countries
or regions to maximize the coverage of HPV vaccination
campaigns.
Conclusions
These results suggest that local organizations and insti-
tutions can implement successful HPV vaccination cam-
paigns. Mixed models comprising both school and
health facility settings appear to be the most effective at
delivering HPV vaccine to target girls aged 9-13 years.
Such mixed models may increase the performance of
other vaccination programs and may also be relevant to
the delivery of other care or preventive services for
school-aged children. Partnership between schools and
health facilities may also increase the delivery of services
to girls who are not in school, although this may requireintensive resources in order to reach those who do not
have formal or routine contact with schools or health
programs. The data reported here provide lessons for
development of public health programs and policies as
countries go forward in national decision-making for
HPV vaccination.
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